Inactive Instrument

Analyst Reco. Freeline Therapeutics Holdings plc

Equities

FRLN

US35655L2060

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

HC Wainwright Downgrades Freeline Therapeutics to Neutral From Buy, Adjusts Price Target to $6.50 From $15	Nov. 28	MT
Wedbush Downgrades Freeline Therapeutics to Neutral From Outperform, Cuts Price Target to $5 From $8	23-10-18	MT
Wedbush Adjusts Freeline Therapeutics Price Target to $8 From $5, Maintains Outperform Rating	23-10-04	MT
Stifel Adjusts Price Target on Freeline Therapeutics to $4 From $3, Keeps Hold Rating	23-08-16	MT
Wedbush Raises Price Target on Freeline Therapeutics to $5 From $1, Maintains Outperform Rating	23-05-30	MT
HC Wainwright Lowers Price Target on Freeline Therapeutics to $2 From $15, Maintains Buy Rating	23-04-05	MT
Stifel Downgrades Freeline Therapeutics to Hold From Buy, Adjusts Price Target to $1 From $2	23-04-05	MT
Wedbush Cuts Freeline Therapeutics Price Target to $1 From $3, Maintains Outperform Rating	23-04-04	MT
HC Wainwright Adjusts Price Target on Freeline Therapeutics Holdings to $15 From $20, Reiterates Buy Rating	22-08-22	MT
BTIG Lowers Freeline Therapeutics Holdings' Price Target to $5 From $10, Keeps Buy Rating	22-08-11	MT
Wedbush Adjusts Price Target for Freeline Therapeutics Holdings to $3 From $6, Maintains Outperform Rating	22-07-11	MT
Stifel Adjusts Freeline Therapeutics Holdings' Price Target to $10 from $12, Maintains Buy Rating	22-04-04	MT
Wedbush Lowers Price Target for Freeline Therapeutics to $6 From $10, Maintains Outperform Rating	22-04-01	MT
Morgan Stanley Downgrades Freeline Therapeutics Holdings to Equalweight From Overweight, Adjusts Price Target to $2 From $9	22-02-01	MT
Redburn Upgrades Freeline Therapeutics Holdings to Buy from Neutral	22-01-07	MT
Wedbush Trims Price Target on Freeline Therapeutics Holdings to $10 From $12 on FLT210 Update; Outperform Rating Kept	21-12-14	MT
BTIG Starts Freeline Therapeutics Holdings at Buy With $10 Price Target	21-11-29	MT
Wedbush Trims Price Target on Freeline Therapeutics Holdings to $12 From $14, Citing Launch Timelines; Outperform Rating Kept	21-11-10	MT
FREELINE THERAPEUTICS : Morgan Stanley Adjusts Freeline Therapeutics Holdings' Price Target to $9 from $22, Keeps Overweight Rating	21-10-19	MT
FREELINE THERAPEUTICS : HC Wainwright Adjusts Price Target on Freeline Therapeutics Holdings to $20 From $30, Maintains Buy Rating	21-08-18	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Freeline Therapeutics Holdings plc

Equities

FRLN

US35655L2060

Analyst Reco.

Filters